Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
84
NCT00615186
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
Phase: Phase 3
Role: Lead Sponsor
Start: Jun 30, 2008
Completion: Dec 31, 2013
NCT00906516
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Phase: Phase 2
Start: May 31, 2009
Completion: Dec 31, 2010
NCT04998474
FRAME-001 Personalized Vaccine in NSCLC
Start: Jan 31, 2022
Completion: Jul 31, 2024